Pralatrexate was the first drug approved in the USA to treat R/R PTCL, and it competitively inhibits dihydrofolate reductase (DHFR) (87, 103, 104). The gene discussed is DHFR; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.